Alkem Laboratories is an Indian pharmaceutical formulator with the third-largest domestic branded generic franchise, a growing international generics business, and two nascent but strategically important new segments: a CDMO subsidiary called Enzene and a medical device business anchored by the Occlutech acquisition. The company earned INR 147,123 million of revenue in FY26, up 13.5% year on year, with EBITDA of INR 30,520 million representing a 20.4% margin, up from 19.4% in FY25. The domestic business, which contributes roughly two-thirds of sales, grew 9.7% to INR 98,514 million, outperforming the Indian pharmaceutical market by 100-150 basis points as guided, while the chronic segment now accounts for about 22% of branded generics and is gaining roughly one percentage point of share per year. International sales grew 22.5% to INR 46,100 million, driven by US launches such as sacubitril/valsartan and strong non-US markets like Germany and Australia. The CDMO and MedTech segments together contribute less than 1% of revenue today, but they hold explicit INR 1,000 crore revenue ambitions within 3-5 years, positioning them as meaningful diversifiers over the horizon.
The persistence of Alkem's economics rests on its field force and brand equity in Indian chronic therapies. It has consistently outperformed the IPM in six of its key therapeutic areas, with growth multiples ranging from 1.2x in respiratory to 3.1x in GI and derma, and its anti-diabetic portfolio grew at twice the market rate excluding GLP-1. Field force attrition has been reduced to 18-19%, below the industry average, which sustains prescription momentum. In the US, the base business is flattish, making new product launches critical, but the company has shown it can capture early share, as evidenced by semaglutide achieving 11% unit market share in its first IQVIA report after a March 2026 launch. The MedTech arm brings higher barriers through Occlutech: regulatory approvals in the US, Europe, Japan and Australia, a 23% market share in Europe for its cardiac occluders, and a pipeline targeting the $1.4 billion left atrial appendage device market that is currently a duopoly of Abbott and Boston Scientific. The trade generics business, however, is highly competitive, and management has deliberately traded growth for margin there, so the moat is strongest in chronic prescription brands and in device approval cycles.
The inflecting factors over the next 18-24 months are semaglutide's penetration, Occlutech's integration, and Enzene's US CDMO scale-up. Semaglutide, launched in March 2026, is the top priority for FY27, and the oral tablet formulation is in clinical trials with a US filing planned in about 1.5 years, extending the opportunity beyond India. The Occlutech acquisition, expected to close within 45-60 days of the June 2026 call, brings a 55% stake for an initial INR 1,100 crore, with an additional INR 100-200 crore to accelerate R&D over two years. The PFO occluder is slated for US approval and launch by June 2027, carrying an average selling price of about $9,500, while the LAA device targets a European launch within three years. Management guides Occlutech to 10% EBITDA by FY27 and 23-24% within three years, while Alkem MedTech as a whole targets INR 1,000 crore revenue and 20-25% EBITDA in 3-5 years; the incremental investment of INR 200-300 crore over 3-4 years is mostly already spent. Enzene's US CDMO plant, commissioned in September 2025, is targeting a INR 300 crore annual run rate in 12-18 months, with the India arm already EBITDA positive at early double-digit margins. By mid-2027 to mid-2028, the core pharma business should grow 10-12%, the chronic mix may exceed 25% of branded generics, and Occlutech's base revenue (INR 600 crore in calendar 2026, growing at 14% CAGR from existing products) will contribute several hundred crore of group revenue, while the group EBITDA margin stays in the 20-21% range for FY27 and could expand once geopolitical cost pressures abate.
Management has a consistent record of delivering on stated numbers. For FY26, they guided to an EBITDA margin of 19.5-20%, and the actual came in at 20.4%. The India growth guidance of 100-150 bps over IPM was met, with domestic sales growing 9.7% against an IPM of roughly 8% in Q4. They also promised high single-digit US growth for FY26, and Q1 delivered 8.8% on a constant-currency basis. The semaglutide day-one launch and 11% initial share exceeded expectations. For FY27, they have not cut guidance: they reaffirmed the 100-150 bps India outperformance and now expect EBITDA margin of 20-21%, citing geopolitical cost headwinds in logistics, API, and packaging, while clearly saying clarity on these costs will emerge by Q2/Q3 of FY27. Importantly, they revised the FY27 tax rate guidance down to 27-29% from an earlier 35-38% under the new tax regime, which improves net earnings visibility. They have committed to no further acquisitions for at least 12 months, focusing on integrating Occlutech, and the CEO search is underway with top global headhunters. The one deviation is the trade generics business, which grew only 4.3% in FY26 after being carved out as a separate entity, but management frames this as a deliberate margin-improvement move, with that segment now nearly at corporate margins.
The quantified earnings path over 18-24 months is a domestic growth of 10-11% (IPM plus 100-150 bps), US high single-digit constant-currency growth with new launches in H2 FY27, ROW high teens, and a tax rate falling from the 35-38% range to 27-29% under the new regime. This supports a low-to-mid-teens PAT CAGR even with EBITDA margin flat at 20-21%. The most critical watchpoint is the June 2027 PFO occluder approval in the US; any slip would push the highest-ASP device into FY28 and weaken the MedTech narrative. Similarly, semaglutide unit share must hold above the initial 11% and grow as the oral formulation advances. The tension between Q4 FY26's 14.4% EBITDA margin and the full-year 20.4% is explained by one-time due diligence costs, foreign currency impact, and renovation expenses, not a structural decline, since quarterly margins in Q2 and Q3 were 23% and 22.2% respectively. If cost pressures persist beyond Q1-Q2 FY27, the 20-21% guidance already incorporates those headwinds, and management has promised better clarity by Q2/Q3 FY27. The falsifier would be a miss on India outperformance or a delay in Occlutech integration, but based on the existing track record, the most probable state at the end of this period is a pharma core growing double-digit with MedTech and CDMO contributions just beginning to move the group metrics.
companyname: Alkem Laboratories Limited ticker: ALKEM sector: Pharmaceuticals / Healthcare (generics, biosimilars, MedTech, CDMO) Alkem is a Mumbai-headquartered healthcare company founded in 1973. It makes and sells branded generic pharmaceuticals, biosimilars, contract-manufactured biologics, medical devices, APIs, and consumer wellness products across 40-plus countries. In FY2026, revenue reached ₹1,47,123 million, up 13.5%, with EBITDA of ₹30,052 million at a 20.4% margin (Q4 FY26 concall, ...
Read the full report →capex, regulatory approval, new product segment, acquisition inorganic
No guidance
Guidance maintainedconsistent
Get valuation models, detailed research reports, thematic primers, one-pagers, risk analysis, growth triggers, bear case, capex tracker, walk the talk, and more for Alkem Laboratories Limited and 4,900+ companies.
5-day free pass. No card required.